Sage Therapeutics (NASDAQ:SAGE) PT Lowered to $13.00 at Robert W. Baird

Sage Therapeutics (NASDAQ:SAGE) had its price target cut by Robert W. Baird from $15.00 to $13.00 in a research note published on Thursday, Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also weighed in on SAGE. StockNews.com upgraded Sage Therapeutics from a sell rating to a hold rating in a research note on Saturday, April 27th. Bank of America lowered Sage Therapeutics from a neutral rating to an underperform rating and decreased their target price for the stock from $24.00 to $14.00 in a research note on Wednesday, April 17th. Scotiabank decreased their target price on Sage Therapeutics from $34.00 to $19.00 and set a sector outperform rating on the stock in a research note on Thursday, April 18th. The Goldman Sachs Group cut their price objective on Sage Therapeutics from $28.00 to $19.00 and set a neutral rating for the company in a report on Friday, April 26th. Finally, Mizuho cut their price objective on Sage Therapeutics from $18.00 to $16.00 and set a neutral rating for the company in a report on Friday, July 19th. Two analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of Hold and an average target price of $33.55.

Sage Therapeutics Trading Up 5.0 %

NASDAQ:SAGE opened at $10.99 on Thursday. Sage Therapeutics has a 52-week low of $9.73 and a 52-week high of $37.17. The business’s fifty day moving average is $11.28 and its 200 day moving average is $16.82.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). The business had revenue of $7.90 million during the quarter, compared to the consensus estimate of $5.26 million. Sage Therapeutics had a negative return on equity of 56.81% and a negative net margin of 552.52%. Sage Therapeutics’s revenue was up 139.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.46) earnings per share. Research analysts forecast that Sage Therapeutics will post -6.65 earnings per share for the current year.

Institutional Investors Weigh In On Sage Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Trexquant Investment LP purchased a new stake in Sage Therapeutics in the 4th quarter worth approximately $2,234,000. Vanguard Group Inc. lifted its holdings in Sage Therapeutics by 3.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,208,002 shares of the biopharmaceutical company’s stock worth $107,181,000 after buying an additional 175,565 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Sage Therapeutics by 1,049.2% in the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 201,107 shares of the biopharmaceutical company’s stock worth $4,358,000 after buying an additional 183,607 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Sage Therapeutics by 1,058.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 156,593 shares of the biopharmaceutical company’s stock worth $2,935,000 after buying an additional 143,075 shares during the period. Finally, abrdn plc purchased a new stake in Sage Therapeutics in the 4th quarter worth approximately $1,404,000. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.